Erasca Stock Gets Buy Rating: Analyst Sees Huge Potential in Cancer Drug
Stifel initiates Erasca coverage with Buy rating and $4 target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition.
/ 1680 items
#XY↓
BofA Sees Big Potential in Vera Therapeutics' Autoimmune Drug
Bank of America starts coverage on Vera Therapeutics with Buy rating and $48 target, citing Atacicept's potential in multibillion-dollar autoimmune disease market.
Truist Sees Major Upside in Terns Pharmaceuticals Stock
Truist initiates Terns Pharmaceuticals with Buy rating and $20 target, citing promising blood cancer drug and oral GLP-1 treatment potential.
Hers Launches Specialized Menopause and Perimenopause Care to Close Major Healthcare Gap
Hers launched specialty care for menopause/perimenopause, offering women personalized plans including prescription pills, patches, or creams.
Omeros Strikes $2.1 Billion Deal, Granting Novo Nordisk Exclusive Global Rights to Zaltenibart
Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.
Wells Fargo Upgrades Apellis to Overweight - $32 Price Target
Wells Fargo raises Apellis to Overweight with $32 target, citing stable Syfovre sales and strong Empaveli launch potential. Stock could gain 15-20%.